Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3701_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
34 Мб
Скачать
Predicting Risk of Emerging Cardiotoxicity DOI: http://dx.doi.org/10.5772/.105040
The Journal of Allergy and Clinical
371
https://t.me/medicina_free
Immunology in Practice (Cambridge, MA). 2020;(1):188-194.e8. DOI: 10.1016/j.jaip.2019.06.043
[29]
Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological Reviews. 2008;(2):581-609. DOI: 10.1152/ physrev.00024.2007
[30]
Heusch G. Myocardial ischemia­reperfusion injury and cardioprotection in perspective. Nature Reviews in Cardiology. 2020;:773-789
[31]
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. The New England Journal of Medicine. 2007;:1121-1135. DOI: 10.1056/ NEJMra071667
2020;:1764-1774. DOI: 10.1661/ CIRCULATIONAHA119.044408
[37] Kaya Z, Leib C, Katus H.
Autoantibodies in heart failure and cardiac dysfunction. Circulation Research. 2012;(1):145-158. DOI:
10.1161.CIRCRESAHA.111.243360
[38] Khamsi R. Rogue antibodies could
be driving severe COVID-19. Nature. 2021;:29-31
[39] Blagova O, Varionchik N,
Zaidenov V, Savina P, Sarkisova N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. European Journal of Immunology. 2021;:893-902. DOI: 10.1002/ eji.202048930
[32]
Hausenloy DJ, Candilio L, Evans R, Cono A, Jenkins DP, Kolvekar S, et al. The New England Journal of Medicine. 2015;:1408-1417. DOI: 10.1056/ NEJMoa1413534
[33]
Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al. Air Polution and cardiovascular disease. Circulation. 2004;(21):2655-2271
[34]
Franklin BA, Brook R, Pope CA III. Air pollution and cardiovascular disease. Current Problems in Cardiology. 2015;:207-238
[35]
Al-Kindi SG, Brook RD, Bisawal S, Rajagopalan S. Environmental determinants of cardiovascular disease: Lessons learned from air pollution. Nature Reviews Cardiology. 2020;(17):656-672
[36]
Maguy A, Tardif J-C, Busseuil D, Ribi C, Li J. Autoantibody signature in cardiac arrest. Circulation.

[40] Carll AP, Willis MS, Lust RM,
Costa DL, Farraj AK. Merits of non­invasive rat models of left ventricular heart failure. Cardiovascular Toxicology. 2011;(2):91-112. DOI: 10.1007/s12012- 011-9103-5 PMID: 21279739
[41] Corremans R, Adão R, De
Keulenaer GW, Leite-Moreira AF, Brás-Silva C. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Clinical and Experimental Pharmacology & Physiology. 2019;(3):204-215. DOI: 10.1111/1440-1681.13036 PMID: 30244497
[42] Timm KN, Tyler DJ. The role of
AMPK activation for Cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovascular Drugs and Therapy 2020;(2):255-269. DOI: 10.1007/ s10557-020-06941-x. PMID: 32034646; PMCID: PMC7125062. 8
[43] Kang YJ. Molecular and cellular
mechanisms of cardiotoxicity.
Novel Pathogenesis and Treatments for Cardiovascular Disease
372
https://t.me/medicina_free
Environmental Health Perspectives. 2001;(Suppl. 1):27-34. DOI: 10.1289/ ehp.01109s127
[44] Fabiani I, Aimo A, Grigoratos C,
etal. Oxidative stress and inflammation: Determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Failure Reviews. 2021;:881-890. DOI: 10.1007/ s10741-020-10063-9
[45] Zhang S, Liu X, Bawa-Khalfe T, etal.
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine. 2012;:1639-1642. DOI: 10.1038/nm.2919
[46] Zhu H, Sarkar S, Scott L, Danelisen I,
Trush MA, Jia Z, et al. Doxorubicin redox biology: Redox cycling, topoisomerase inhibition, and oxidative stress. Reactive Oxygen Species (Apex, N.C.). 2016;(3):189-198. DOI: 10.20455/ ros.2016.83513
[47] Rabinovich-Nikitin I,
Love M, Kirshenbaum LA. Inhibition of MMP prevents doxorubicin-induced cardiotoxicity by attenuating cardiac intracellular and extracellular matrix remodelling. Cardiovascular Research. 2021;(1):11-12. DOI: 10.1093/cvr/ cvaa198
[48] Aries A, Paradis P, Lefebvre C,
Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug­induced cardiotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 2004;(18):6975-6980. DOI: 10.1073/ pnas.0401833101
[49] Park AM, Nagase H, Liu L, Vinod
Kumar S, Szwergold N, Wong CM, et al. Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart. Cardiovascular Research. 2011;(1):97-
104. DOI: 10.1093/cvr/cvq36110

[50] Dudek J, Hartmann M, Rehling P.
The role of mitochondrial cardiolipin in heart function and its implication in cardiac disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2019;(4):810-821. DOI: 10.1016/j. bbadis.2018.08.025
[51] Zhao L, Zhang B. Doxorubicin
induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Scientific Reports. 2017;:44735. DOI: 10.1038/ srep44735
[52] Nakamura T, Ueda Y, Juan Y,
Katsuda S, Takahashi H, Koh E. Fas­mediated apoptosis in adriamycin­induced cardiomyopathy in rats: In vivo study. Circulation. 2000;(5):572-578. DOI: 10.1161/01.cir.102.5.572
[53] Guo R, Xu W, Lin J, Mo L,
Hua X, Chen P, et al. Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Molecular Medicine Reports. 2013;:603-
608. DOI: 10.3892/mmr.2013.1554
[54] Putt M, Hahn VS, Januzzi JL,
Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast Cancer patients treated with doxorubicin, Taxanes, and Trastuzumab. Clinical Chemistry. 2015;(9):1164-1172. DOI: 10.1373/ clinchem.2015.241232
[55] Beer LA,Kossenkov AV, Liu Q ,
Luning Prak E, Domchek S, Speicher DW, et al. Baseline immunoglobulin E levels as a marker of doxorubicin- and Trastuzumab-associated cardiac dysfunction. Circulation Research. 2016;(10):1135-1144. DOI: 10.1161/ CIRCRESAHA.116.309004
Predicting Risk of Emerging Cardiotoxicity DOI: http://dx.doi.org/10.5772/.105040
[56]
373
https://t.me/medicina_free
Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: A focus on cardiotoxicity. European Cardiology. 2018;(1):64-69. DOI: 10.15420/ecr.2017:17:2
[57]
Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology. 2015;(9):H1453-H1467. DOI: 10.1152/ ajpheart.00554.2015
[58]
Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy. Journal of the American College of Cardiology. 2004;(11):2231-2238. DOI: 10.1016/j. jacc.2004.08.066
[59]
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine. 2002;(5):459-465. DOI: 10.1038/ nm0502-459
[60]
Vasti C, Hertig CM. Neuregulin-1/ erbB activities with focus on the susceptibility of the heart to anthracyclines. World Journal of Cardiology. 2014;(7):653-662. DOI: 10.4330/wjc.v6.i7.653
[61]
Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sciences. 2019;:112-131. DOI: 10.1016/j.lfs.2018.12.018
[62]
Omole JG, Ayoka OA, Alabi QK, Adefisayo MA, Asafa MA, Olubunmi BO, et al. Protective effect of Kolaviron

on cyclophosphamide-induced cardiac toxicity in rats. Journal of Evidence-Based Integrative Medicine. 2018;:2156587218757649. DOI: 10.1177/2156587218757649
[63] Al-Nasser IA. In vivo prevention
of cyclophosphamide-induced Ca2+ dependent damage of rat heart and liver mitochondria by cyclosporin a. Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology. 1998;(3): 209-214. DOI: 10.1016/s1095-6433(98) 10135-6
[64] Asiri YA. Probucol attenuates
cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues. Oxidative Medicine and Cellular Longevity. 2010;(5):308-
316. DOI: 10.4161/oxim.3.5.13107
[65] Avci H, Epikmen ET, Ipek E,
Tunca R, Birincioglu SS, Akşit H, etal. Protective effects of silymarin and curcumin on cyclophosphamide-induced cardiotoxicity. Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft fur Toxikologische Pathologie. 2017;(5):317-327. DOI: 10.1016/j.etp.2017.02.002
[66] Refaie MMM, Shehata S,
El-Hussieny M, et al. Role of ATP­sensitive Potassium Channel (KATP) and eNOS in mediating the protective effect of Nicorandil in cyclophosphamide­induced cardiotoxicity. Cardiovascular Toxicology. 2020;:71-81. DOI: 10.1007/ s12012-019-09535-8
[67] Lushnikova EL, Nepomnyashchikh
LM, Sviridov EA, et al. Ultrastructural signs of cyclophosphamide-induced damage to cardiomyocytes. Bulletin of Experimental Biology and Medicine. 2008; :366-371. DOI: 10.1007/ s10517-008-0287-z
Novel Pathogenesis and Treatments for Cardiovascular Disease
374
https://t.me/medicina_free
[68] Carlson LE, Watt GP,
Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. Coronary artery disease in young women after radiation therapy for breast Cancer: The WECARE study. JACC: CardioOncology. 2021;(3):381-
392. DOI: 10.1016/j.jaccao.2021.07.008 PMID: 34604798; PMCID: PMC8463731
[69] Correa CR, Litt HI, Hwang WT,
Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. Journal of Clinical Oncology. 2007;(21):3031-
3037. DOI: 10.1200/JCO.2006.08.6595 PMID: 17634481
[70] Sardar P, Kundu A, Chatterjee S,
Nohria A, Nairooz R, Bangalore S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. Clinical Cardiology. 2017;(2):73-81. DOI: 10.1002/clc.22631 PMID: 28244595; PMCID: PMC6490535
[71] Jimenez RB, Wong SM, Johnson A,
Lalani N, Hughes KS. The association between cardiac mortality and adjuvant radiation therapy among older patients with stage I Estrogen positive breast Cancer: A surveillance, epidemiology, and end results (SEER)-based study on cardiac mortality and radiation therapy. Advances in Radiation Oncology. 2020;(2):100633. DOI: 10.1016/j. adro.2020.100633 PMID: 33912735; PMCID: PMC8071719
[72] Gardner DG, Chen S, Glenn DJ.
Vitamin D and the heart. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2013;(9):R969-R977. DOI: 10.1152/ ajpregu.00322.2013
[73] Polat V, Bozcali E, Uygun T,
Opan S, Karakaya O. Low vitamin D status associated with dilated

cardiomyopathy. International Journal of Clinical and Experimental Medicine. 2015;(1):1356-1362
[74]
Chiodini I, Gatti D, Soranna D, Merlotti D, Mingiano C, Fassio A, etal. Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Frontiers in Public Health. 2021;:736665. DOI: 10.3389/ fpubh.2021.736665 PMID: 35004568; PMCID: PMC8727532
[75]
Sciatti E, mbardi C, Ravera A, Vizzardi E, Bonadei I, Carubelli V, et al. Nutritional deficiency in patients with heart failure. Nutrients. 2016;(7):442. DOI: 10.3390/nu8070442
[76]
Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme Q10 on statin-induced myopathy: An updated Meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2018;(19):e009835. DOI: 10.1161/JAHA.118.009835. PMID: 30371340; PMCID: PMC6404871
[77]
Langsjoen PH, Langsjoen JO, Langsjoen AM, Rosenfeldt F. Statin­associated cardiomyopathy responds to statin withdrawal and administration of coenzyme Q10. The Permanente Journal. 2019;:18-257. DOI: 10.7812/ TPP/18.257 PMID: 31496499; PMCID: PMC6730959
[78]
Jiang J-B, Balschi JA Jr, F. X., & He, H. Thiazolidinediones cause cardiotoxicity via PPARγ- independent mechanism. Cardiotoxicity. 2018. DOI: 10.5772/.78957
[79]
Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of PPARα is detrimental to cardiac recovery after ischemia. American Journal of Physiology. Heart and Circulatory Physiology. 2006;:H87-H95
Predicting Risk of Emerging Cardiotoxicity DOI: http://dx.doi.org/10.5772/.105040
[80]
375
https://t.me/medicina_free
Baik A, Oluwole O, Johnson D, Shah N, Salem J-E, et al. Cardiovascular toxicities and immunotherapies. Circulation Research. 2021; (11):1780-1801. DOI: 10.1161/ CIRCRESAHA.120.315894
[81]
Woodward TE, FR MC Jr, Carey TN, Togo Y. Viral and rickettsial causes of cardiac disease, including the Coxsackie virus etiology of pericarditis and myocarditis. Annals of Internal Medicine. 1960;:1130-1150. DOI: 10.7326/0003-4819-53-6-1130 PMID: 13786607
[82]
Kim KS, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Reviews in Medical Virology. 2001;(6):355-368. DOI: 10.1002/rmv.326 PMID: 11746998
[83]
Tam PE. Coxsackie virus myocarditis: Interplay between virus and host in the pathogenesis of heart disease. Viral Immunology. 2006;(2):133-146. DOI:10.1089/vim.2006.19.133 PMID:16817756
[84]
Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: A model of autoimmune disease for studying immunotoxicity. Methods. 2007;(1):118-122. DOI: 10.1016/j. ymeth.2006.07.009. PMID: 17161308; PMCID: PMC1764911
[85]
Freiberg MS, So-Armah K. HIV and cardiovascular disease: We need a mechanism, and we need a plan. Journal of the American Heart Association. 2016;(3):e003411. DOI: 10.1161/ JAHA.116.003411. PMID: 27013540; PMCID: PMC4943288
[86]
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, etal. HIV infection and the risk of acute myocardial infarction. JAMA Internal Medicine. 2013;:614-622

[87] Butt AA, Chang CC,
Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Archives of Internal Medicine. 2011;:737-743
[88] Ni W, Yang X, Yang W, Bao J, Xiao Y,
et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care. 2020;:422. DOI: doi.org/10.1186/ s13054-020-03120-0
[89] Libby P, Lüscher T. COVID-19 is, in
the end, an endothelial disease. European Heart Journal. 2020;(32):3038-3044. DOI: 10.1093/eurheartj/ehaa623 PMID: 32882706; PMCID: PMC7470753
[90] Evans PC, Rainger GE, Mason JC,
Guzik TJ, Osto E, Stamataki Z, et al. Endothelial dysfunction in COVID-19: A position paper of the ESC working Group for Atherosclerosis and Vascular Biology, and the ESC Council of basic cardiovascular science. Cardiovascular Research. 2020;(14):2177-2184. DOI: 10.1093/cvr/cvaa230 PMID: 32750108; PMCID: PMC7454368
[91] Puntmann V, Carej M, Wieters I,
Fahim M, Arendt C, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-
19). JAMA Cardiology. . DOI: 10.1001/jamacardio.2020.3557
[92] Nishiga M, Wang DW,
Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nature Reviews. Cardiology 2020;(9):543-558. DOI: 10.1038/ s41569-020-0413-9. PMID: 32690910; PMCID:PMC7370876.
[93] Guzik TJ, Mohiddin SA, Dimarco A,
Patel V, Savvatis K, Marelli-Berg FM,
Novel Pathogenesis and Treatments for Cardiovascular Disease
376
https://t.me/medicina_free
et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research. 2020;(10):1666-1687. DOI: 10.1093/ cvr/cvaa106 PMID: 32352535; PMCID: PMC7197627
[94] Ratchford SM, Stickford JL,
Province VM, Stute N, Augenreich MA, Koontz LK, et al. Vascular alterations among young adults with SARS-CoV-2. American Journal of Physiology. Heart and Circulatory Physiology. 2021;(1):H404-H410. DOI: 10.1152/ ajpheart.00897.2020 PMID: 33306450; PMCID: PMC8083172
[95] Hazarika S, Van Scott MR,
Lust RM. Airborne allergen increases severity of myocardial injury following ischemia-reperfusion in allergic mice. American Journal of Physiology. Heart and Circulatory Physiology. 2007;(1):H572-H579. PMID: 16905595
[96] Hazarika S, Van Scott MR, Lust RM,
Wingard CJ. Pulmonary allergic reactions impair systemic vascular relaxation in ragweed sensitive mice. Vascular Pharmacology. 2010;(5-6):258-263 PMID: 20888432
[97] Wingard CJ, Cozzi E, van Scott MR,
Lust RM. Particulate exposures and cardiovascular inflammation. Chapter 5. In: Meggs W, editor. Toxicant Induction of Irritant Asthma, Rhinitis, and Related Conditions. New York: Springer; 2013. ISBN 978-1-4614-9043-2
[98] Brook RD. Why physicians
whotreat hypertension should know more about air pollution. The Journal ofClinical Hypertension. 2007;(8):629-635. DOI: 10.1111/ j.1524-6175.2007.07187.x
[99] Lee BJ, Kim B, Lee K. Air pollution
exposure and cardiovascular disease.

Toxicology Research. 2014;(2):71-75. DOI: 10.5487/TR.2014.30.2.071
[100] Simkhovich BZ, Kleinman MT,
Kloner RA. Air pollution and cardiovascular injury. Journal of the American College of Cardiology. 2008;(9):719-726. DOI: 10.1016/j. jacc.2008.05.029
[101] Bourdrel T, Bind MA, Béjot Y,
Morel O, Argacha JF. Cardiovascular effects of air pollution. Archives of Cardiovascular Diseases. 2017;(11):634-642. DOI: 10.1016/j. acvd.2017.05.003
[102] Bostan HB, Rezaee R, Valokala MG,
et al. Cardiotoxicity of nano-particles. Life Sciences. 2016;:91-99. DOI: 10.1016/j.lfs.2016.09.017
[103] Gold DR, Litonjua A,
Schwartz J, et al. Ambient pollution and heart rate variability. Circulation. 2000;(11):1267-1273. DOI: 10.1161/
01.cir.101.11.1267
[104] Cozzi E, Hazarika S, Stallings HW,
Cascio WE, Devlin RB, Lust RM, et al. Ultrafine particulate matter exposure augments ischemia reperfusion injury in mice. American Journal of Physiology. Heart and Circulatory Physiology. 2006;(2):H894-H903. PMID: 16582015
[105] Cascio WE, Cozzi E, Devlin RB,
Henriksen RA, Lust RM, Van Scott MR, et al. Cardiac and vascular changes in mice after exposure to ultrafine particulate matter. Inhalation Toxicology. 2007;(Suppl. 1):67-73 PMID: 17886053
[106] Cozzi E, Wingard CJ, Cascio WE,
Devlin RB, Miles JJ, Bofferding AR, etal. Effect of ambient particulate matter exposure on hemostasis. Translational Research. 2007;(6):324-332. PMID: 17543851
Predicting Risk of Emerging Cardiotoxicity DOI: http://dx.doi.org/10.5772/.105040
[107]
377
https://t.me/medicina_free
Carll AP, Lust RM, Hazari MS, Perez CM, Krantz QT, King CJ, et al. Diesel exhaust inhalation increases cardiac output, bradyarrhythmias, and parasympathetic tone in aged heart failure-prone rats. Toxicological Sciences. 2013, 2013;(2):583-595. PMID:23047911
[108]
Kan H, Pan D, Castranova V. Engineered nanoparticle exposure and cardiovascular effects: The role of a neuronal-regulated pathway. Inhalation Toxicology. 2018;(9-10):335-342. DOI: 10.1080/08958378.2018.1535634
[109]
Wingard CJ, Walters DM, Cathey BL, Hilderbrand SC, Katwa P, Lin S, et al. Mast cells contribute to altered vascular reactivity and ischemia-reperfusion injury following cerium oxide nanoparticle instillation. Nanotoxicology. 2011;(4):531-545. PMID: 20888432
[110]
Thompson LC, Urankar RN, Holland NA, Vidanapathirana AK, Pitzer JE, Han L, et al. C60 exposure augments cardiac ischemia/reperfusion injury and coronary artery contraction in Sprague-Dawley rats. Toxicological Sciences. 2014;(2):365-378. DOI:10.1093/toxsci/kfu008 PMID:24431213
[111]
Holland NA, Becak DP, Shannahan JH, Brown JM, Carratt SA, Van Winkle LS, et al. Cardiac ischemia reperfusion injury following instillation of 20 nm citrate-capped Nanosilver. Journal of Nanomedicine & Nanotechnology. 2015;S. DOI: 10.4172/2157-7439.S6-006 PMID:26966636
[112]
Holland NA, Thompson LC, Vidanapathirana AK, Urankar RN, Lust RM, Fennell TR, et al. Impact of pulmonary exposure to gold core silver nanoparticles of different size and capping agents on cardiovascular

injury. Particle and Fibre Toxicology. 2016;(1):48-69. DOI: 10.1186/s12989­016-0159-z PMID:27558113
[113] Urankar RM, Lust RM,
Mann E, Katwa P, Wang X, Podila R, et al. Expansion of cardiac ischemia/ reperfusion injury after instillation of three forms of multi-walled carbon nanotubes. Particle and Fibre Toxicology. 2012;(9):38 PMID:23072542
[114] Gottumukkala RV, Lv H,
Cornivelli L, Wagers AJ, Kwong RY, Bronson R, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Science Translational Medicine. 2012;(138):138ra80. DOI:10.1126/scitranslmed.3003551 PMID: 22700956; PMCID: PMC4303259
[115] Frustaci A, Cuoco L, Chimenti C,
Pieroni M, Fioravanti G, Gentiloni N, et al. Celiac disease associated with autoimmune myocarditis. Circulation. 2002;(22):2611-2618. DOI:10.1161/01. cir.0000017880.86166.87. PMID:12045166
[116] Al-Hussaini A, Sulaiman N,
Al-Zahrani M, Alenizi A, El Haj I. High prevalence of celiac disease among Saudi children with type 1 diabetes: A prospective cross-sectional study. BMC Gastroenterology. 2012;:180. DOI:10.1186/1471-230X-12-180. PMID:23259699; PMCID: PMC3543703
[117] Sousa GR, Niewczas M. Lipes MA;
251-OR: Cardiac autoantibodies (AB) predict cardiovascular disease (CVD) in T1D and are associated with cytokine signatures linked to CVD risk. Diabetes. 2020;(Supplement_1) 251–OR. DOI:10.2337/db20-251-OR
[118] Caforio A, Mahon N,
Tona F, McKenna W. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: Pathogenetic and
Novel Pathogenesis and Treatments for Cardiovascular Disease
378
https://t.me/medicina_free
clinical significance. European Journal of Heart Failure. 2002;-
[119] Caforo A, Tona F, Bottaro S, Vinvi A,
Dequal G, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008;:35-45. DOI:10.1080.08916930701619235
[120] Moraru M, Roth A, Keren G,
George J. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. International Journal of Cardiology. 2006;:61-66. DOI: 10.1016/j.ijcard.2005.02.036
[121] Calabrese F, Thiene G. Myocarditis
and inflammatory cardiomyopathy: Microbiological and molecular biological aspects. Cardiovascular Research. 2003;:11-25. DOI: 10.1016/ S008-6363(03)00475-9
[122] Mandal K, Jahangiri J, Mukhin M,
Poloniecki J, Camm A, et al. Association of anti-heat shock protein 65 antibodies with development of postoperative atrial fibrillation. Circulation. 2004:2588-2590. DOI: 10.1161/01. CIR.0000136825.96029.A5
[123] Kossowsky W, Epstein J, Levine R.
Post myocardial infarction syndrome: An early complication acute myocardial infarction. Chest. 1973;:35-40. DOI: 10.1378/chest.63.1.35
to acute rejection of cardiac allografts in miniature swine. Transplantation. 2011;:1187-1191. DOI: 10.1097/ TP.0b013e318218415d
[126] Mascaro-Blanco A, Alvarez K,
Yu X, Lindenfeld J, Olansky L, et al. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity. 2008;:442-453. DOI:10.1080/08916930802031579
[127] Bracamonte-Baran W, Cihakova D.
Cardiac autoimmunity; myocarditis. Advances in Experimental Medicine and Biology. 2017;:187-221. DOI:10.1007/978-3-319-57613-8_10
[128] Mocumbi A, Latif N, Yacoub M.
Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Neglected Tropical Diseases. 2010;(4)
[129] Ono M, Shimizu J, Miyachi Y,
Sakaguchi S. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid­induced TNF receptor family-related protein foxp3-expressing-CD25 and CD25 regulatory T cells. Journal of Immunology. 2006;:4748-4756. DOI:10.4049/jimmunol.176.4748
[124] Deubner N, Berliner D, Schlipp A,
Gelbrich G, Caforio A, et al. Cardiac B1-adrenoceptor autoantibodies in human heart disease: Rationale and design of the etiology, time-course, and survival (ETiCS) study. European Journal of Heart Failure. 2010;:753-7662. DOI:10.1093/eurjhf/hfq072
[125] Sahara H, Meltzer A, Weiss M,
Iwamoto Y, et al. Autoimmune sensitization to cardiac myosin leads
Chapter 18
379
https://t.me/medicina_free
Echocardiographic Prognostic Factors in Pulmonary Hypertension
Gabriela Silvia Gheorghe, Andrei Cristian Dan Gheorghe, Ana Ciobanu and Andreea Simona Hodorogea
Abstract
Pulm
onary h pressure of ≥25 mmHg at rest by right heart catheterization. Echocardiography estimates systolic pulmonary arterial pressure on the tricuspid regurgitation jet velocity, mean and diastolic pressure based on the pulmonary regurgitation jet, and data regarding the function of the right ventricle. ESC guidelines propose an echocardiographic risk assess­ment in PH according to right atrial area > 26 cm factors correlated with the severity of the PH include right atrial pressure > 15 mmHg, tricuspid regurgitation more than moderate, TAPSE <18 mm, tricuspid S0 < 11.5 cm/s assessed by TDI, right ventricle ejection fraction < 45% using 3D imaging, fractional area change of the right ventricle < 35%, dP/dt < 400 mmHg/s on the tricuspid regurgitation flow, reduced strain of the right ventricle, diastolic dysfunction. Left ventricular eccen­tricity index (EI) >1.7 combined with TAPSE <15 mm was associated with a higher death rate compared to patients with normal values. However, each of these parameters used in the assessment of the right ventricle has technical limitations, and it is necessary to use multiple tests for a correct evaluation of the prognosis of PH.
Keywords: pulmonary hypertension, tricuspid regurgitation, right ventricle, right atrium, global strain
ypertension (PH) is defined as an increase in mean pulmonary arterial
2
and pericardial effusion. Other risk
1. Introduction
Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure (mPAP) of 25 mmHg at rest as assessed by right heart catheterization. Current data have shown that the normal mPAP at rest is 14 3 mmHg with the upper limit of normal of approximately 20 mmHg. The clinical significance of mPAP between 21 and 24 mmHg is unclear [1]. There are also unclear data regarding the normal versus exaggerated elevation of mPAP at physical effort, making it difficult to put the diagnosis of exercise-induced PH. Pulmonary vascular resistance (PVR) with a cut-off of 3 Wood units has been included in the hemodynamic diagnosis of PH, and pulmonary artery wedge pressure (PAWP) with a cut-off of 15 mmHg is used for the classification of PH in pre-capillary, post-capillary, or combined pre- and post­capillary PH [1]. PH is classified into five groups, depending on the underlying disease [1].
Novel Pathogenesis and Treatments for Cardiovascular Disease
380
https://t.me/medicina_free
Not all patients with PH perform right heart catheterization, and, in practice, the diagnosis of PH is based on the echocardiographic evaluation of the pulmonary artery pressure. Also, echocardiography can detect the underlying disease and the conse­quences of the PH on the right and left ventricles (Table 1), [2–8]. Nevertheless, the echocardiographic evaluation of the right heart is more difficult than that of the left heart because of the complex shape of the right ventricle (RV) and its load-dependent physiology. Its shape in apical 4-chamber view is more triangular, in contrast to the left ventricle more conical. In the parasternal short axis view, it is like a crescent. The cavity of the RV has three parts: inlet, apical trabeculae, and outlet segments. The outlet segment is not trabeculated and is separated from the inlet segment by the supraven­tricular crest. The subepicardial myofibrils have a circumferential orientation, and the subendocardial myofibrils have predominantly a longitudinal orientation [9, 10]. The interventricular septum separates the right and left ventricles and bulges into RV during the ventricular systole. From the three leaflets of the tricuspid valve, the septal leaflet is usually visible by echocardiography. The 2D echography has a low sensitivity for defin­ing the RV endocardial border contour of the free wall and of the apex. The complex morphology of the RV makes the correct echocardiographic evaluation difficult and implies great variation in the 2D measurement results of the RV diameters and area. In a study that included 900 patients, Tamborini G. et al. [11] demonstrated high inter- and intraobserver variabilities in the measurements of RV fractional area change (FAC), a parameter of RV systolic function. There are also difficulties in the echocardiographic examination of the right atria (RA). RA has an ellipsoid shape and includes crista terminalis, RA appendage, cavotricuspid isthmus, Eustachian valve, the orifice of the coronary sinus, and Thebesian valve. Echographic data include RA indexed major and minor axis length and systolic RA volume. The values are different in men and women, and the indexed RA volume using the single-plane method of disks has lower values than those obtained by the area-length method [12]. RA becomes dilated, and a process of RA remodeling occurs in longstanding PH. The RA pressure (RAP) increases, and its evaluation according to the diameter and inspiratory changes of the inferior vena cava (IVC) is an important parameter for the evaluation of RV systolic pressure in the absence of significant RV outflow tract obstruction. The RAP estimated non-invasively is the main source of errors in the assessment of both sPAP and mPAP. sPAP is calculated using the maximal velocity of tricuspid regurgitation flow (Figure 1)and mPAP by formulas that use pulmonary regurgitation flow velocity at the beginning of the diastole or pulmonary velocity acceleration time. Both can underestimate the PH in case of RV failure. RV failure can impede the left ventricle (LV) function by many mechanisms. So assessing the RV and LV morphology and function is essential for the correct diagnosis and prognostic of PH. The echocardiographic evaluation of the right heart can be improved through other methods, such as agitated saline study, echocar­diographic contrast agents, speckle tracking, and 3D echocardiography [13]. 2D RV longitudinal strain of the free wall (RV-FWS) and 2D RV global longitudinal strain (RV­GLS), which includes in the analysis of the interventricular septum, can demonstrate subclinical impairment of the longitudinal contraction in patients with PH. The method is less angle and load-dependent and less influenced by the complex geometry of RV, but it depends on image quality that can be poor because of many artifacts [14, 15]. The analysis of segmental contractility of the RV walls by strain technique offers informa­tion about the pattern of RV remodeling in PH. The cut-off value proposed for RV-FWS is 23% and 20% for RV-GLS. For now, there is no consensus on which method to use, but it seems that RV-FWS is more useful. The 3D technique is more accurate than the 2D technique in the evaluation of RV strain.
2